澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: monobasic sodium phosphate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1-antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

澳大利亚 - 英文 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

brunnings garden products pty ltd - tau-fluvalinate; myclobutanil - other liquids to be applied undiluted - tau-fluvalinate pyrethroid active 0.1 g/l; myclobutanil triazole active 0.05 g/l - mixed function pesticide - ornamental flowering annual | ornamental flowering perenials | rose | shrub | sturt's desert rose - aphid | black spot | helicoverpa spp. | powdery mildew | rust | thrip | two spotted mite | whitefly | corn earworm | cotton bollworm | heliothis | native budworm | red spider mite | scab | spider mite | thrips spp. | tobacco budworm | tomato grub | two-spotted mite | two-spotted spider mite

澳大利亚 - 英文 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

brunnings garden products pty ltd - tau-fluvalinate; myclobutanil - other liquids to be applied undiluted - tau-fluvalinate pyrethroid active 0.1 g/l; myclobutanil triazole active 0.05 g/l - mixed function pesticide - ornamental - flower or shrub | ornamental perennial | ornamental plant or annual | rose | sturt's desert rose - aphid | black spot on rose | carmine mite | helicoverpa spp. | powdery mildew | powdery mildew on rose | rose rust | rust | thrip | whitefly | corn earworm | cotton bollworm | heliothis | native budworm | red spider mite | spider mite | thrips spp. | tobacco budworm | tomato grub | two-spotted mite | two-spotted spider mite

马耳他 - 英文 - Medicines Authority

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - prolonged-release capsule - benserazide 25 mg levodopa 100 mg - anti-parkinson drugs

马耳他 - 英文 - Medicines Authority

rontis hellas medical and pharmaceutical products s.a. 38, sorou str., athens, maroussi, 15125, greece - fampridine - prolonged-release tablet - fampridine 10 mg - other nervous system drugs

美国 - 英文 - NLM (National Library of Medicine)

professional complementary health formulas - l-valine 4x, 7x, 12x - for the temporary relief of stress, anxiousness, nervousness, sleeplessness, or increased appetite.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

美国 - 英文 - NLM (National Library of Medicine)

spectrum pharmaceuticals, inc. - ibritumomab tiuxetan (unii: 4q52c550xk) (ibritumomab tiuxetan - unii:4q52c550xk) - ibritumomab tiuxetan 1.6 mg in 1 ml - zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular b-cell non-hodgkin's lymphoma (nhl). zevalin is indicated for the treatment of previously untreated follicular nhl in adult patients who achieve a partial or complete response to first-line chemotherapy. none. risk summary based on its radioactivity, y-90 zevalin may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . immunoglobulins are known to cross the placenta. there are no available data on zevalin use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. advise women of childbearing potential to use adequate contraception for a minimum of twelve months. inform women who become pregnant while receiving zevalin of the potential fetal risks. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies have a background risk of birth defect, loss, or other

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - diluent, not applicable - excipient ingredients: - prolastin-c is an alpha-1-proteinase inhibitor (human, alpha1-pi) indicated to increase serum alpha1-pi levels in adults with congenital deficiency of alpha-1 antitrypsin and with clinically significant emphysema (fev1 less than 80%). the data for clinical efficacy of prolastin-c is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials. clinical trials have only included patients who were not smoking.